{
    "clinical_study": {
        "@rank": "119421", 
        "arm_group": {
            "arm_group_label": "All Participants", 
            "arm_group_type": "Experimental", 
            "description": "Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years."
        }, 
        "brief_summary": {
            "textblock": "This study is being done to evaluate the safety and efficacy of Pembrolizumab (MK-3475) in\n      participants with advanced non-small cell lung cancer (NSCLC) tumors that are positive for\n      programmed cell death ligand 1 (PD-L1):  the hypothesis is that treatment with pembrolizumab\n      will result in a clinically meaningful overall response rate (ORR)."
        }, 
        "brief_title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of non-small cell lung cancer\n             (NSCLC) that is PD-L1 positive per central laboratory review\n\n          -  At least one measurable lesion.\n\n          -  Radiographic progression of NSCLC after treatment with a platinum-containing doublet\n             for Stage IIIB/IV or recurrent disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks\n             of the first dose of trial treatment\n\n          -  Systemic steroid therapy within 3 days prior to the first dose of trial treatment or\n             any other form of immunosuppressive medication\n\n          -  Expected to require any other form of systemic or localized antineoplastic therapy\n             while on trial\n\n          -  History of prior malignancy, with the exception of basal cell carcinoma of the skin,\n             superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer\n\n          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n          -  Active autoimmune disease or documented history of autoimmune disease or syndrome\n             that requires systemic steroids or immunosuppressive agents\n\n          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or\n             anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody\n\n          -  Concurrent or past history of interstitial lung disease\n\n          -  Pregnant or breast-feeding, or expecting to conceive or father children within the\n             projected duration of the study, starting with screening visit through 120 days after\n             the last dose of pembrolizumab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007070", 
            "org_study_id": "3475-025", 
            "secondary_id": "142500"
        }, 
        "intervention": {
            "arm_group_label": "All Participants", 
            "intervention_name": "Pembrolizumab", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Japan Call Center", 
                "phone": "81-3-6272-1957"
            }, 
            "facility": {
                "address": {
                    "city": "Chiyoda-Ku, Tokyo", 
                    "country": "Japan", 
                    "zip": "102-8667"
                }, 
                "name": "MSD K.K."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Number of participants experiencing adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Number of participants discontinuing study treatment due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression Free Survival (PFS) by RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Duration of response (DOR) by RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}